Announced Date: 2025-08-05 (August 5, 2025)
Licensor: XtalPi Inc. (China)
Licensee: DoveTree Medicines（US）
.
Scope of Collaboration:
Under the agreement, XtalPi will leverage its end-to-end AI drug discovery platform integrating artificial intelligence and robotics to discover and develop small molecule and antibody drug candidates against multiple targets selected by Dovetree.
These targets will primarily focus on oncology, autoimmune diseases, central nervous system (CNS) disorders, and metabolic diseases.
.
Deal Detail:
Upfront payment of $51 million, further payment of $49 million,
Development, regulatory and commercial milestone payments totaling up to $5.89 billion,
Tiered royalties in the mid-single-digit percentage range based on the annual net sales of resulting products.
.
Link:
XtalPi and DoveTree Announce Landmark $6 Billion AI Drug Discovery Collaboration (prnewswire.com)
.
Note:
Chinese Name of XtalPi, 晶泰
